

# **Novel Modes of Global Health Governance**

- Gavi, The Vaccine Alliance (formerly Global Alliance for Vaccines and Immunization)
- International AIDS Vaccine Initiative (IAVI)
- Drugs for Neglected Diseases Initiative (DNDI)
- Africa Centers for Disease Control and Prevention (Africa CDC)
- Foundation for Innovative New Diagnostics (FIND)
- PATH (formerly the Program for Appropriate Technology in Health)
- Coalition for Epidemic Preparedness Innovation: CEPI

Hosted by Martin Kiernan, martin@webbertraining.com www.webbertraining.com 6


# COVID-19 World Preparedness and Response: Lessons Learned


- It is not a crisis it is a new era.
- Multidisciplinary pandemic response networks
  - Collaborations are needed among university, industry, government and communities to merge the efforts and find solutions together.
  - Viral Pandemic Readiness Alliance (VPRA)
- Global and One Health
  - The true international collaborations, can support future pandemic preparedness with distribution of diagnostics, vaccine and therapeutics and other interventional measures.
- Training the next generation of virologists
- Reliable channels for dissemination of scientific knowledge and information sharing




Hosted by Martin Kiernan, martin@webbertraining.com www.webbertraining.com 7


























# <section-header>


O'Brien, J. (2020, March 24), Coronavirus Fear, Retrieved November 11, 2020, from





Hosted by Martin Kiernan, martin@webbertraining.com www.webbertraining.com 19

















Hosted by Martin Kiernan, martin@webbertraining.com www.webbertraining.com






28



# Therapeutic Monoclonal Antibodies Targeting the Spike Protein of SARS-CoV-2

- Preventing viral entry to the cell by binding to the receptorbinding domain (RBD) of the spike protein or blocking the interaction between RBD and the ACE2 receptor
- FDA's approval: Bamlanivimab (LY-CoV555, Eli Lilly); cocktail of casirivimab and imdevimab (Regeneron) for treatment of mild to moderate COVID-19 patients
- Experimental approaches: use of cocktail monoclonal antibodies targeting different epitopes of the S protein
- Effective for early stages of mild and moderate COVID-19
- Required continuous evaluation of safety and effectiveness of these treatments






30

# Therapeutic Monoclonal Antibodies for curving the COVID-19 Cytokine Storm

- Blocking the biological activity of IL-1 and IL-6; Inhibiting JAK signal transducer and activator of transcription pathway
- Clinical outcomes: contradictory Required continuous evaluation of safety and effectiveness for COVID-19 treatment

Randomized clinical trials ongoing on promising inflammatory strategy

Target	Drug Type	Drug (Monoclonal Antibody)
IL 6 signaling	Anti-IL 6	Clazakizumab, Siltuximab
	Anti-IL6 receptor	Sarilumab, Tocilizumab
IL 1 signaling	Anti-IL1β	Canakinumab
	Anti-IL1 repector	Anakinra
JAK-STAT signaling	JAK1/JAK2 inhibitors	Baricitinib, Ruxolitinib
	JAK1/JAK3 inhibitors	Tofacitinib



# COVID19 Treatment When high through put screenings and serendipity helps


>Nitazoxanide: anti-parasitic drug with excellent safety profile and in vitro and in vivo(?) activity against SARS-CoV-2 (Jean-Francois Rossignol, Romark LLC)


>The Nicotine-Nicotinic Acetyl Choline Receptor-COVID19 Connection


(Jean-Pierre Changeux, Institut Pasteur)


>Antiviral sigma-1 receptor ligands: antihistamines in the histamine-1 receptor binding class : diphenhydramine, hydroxyzine and azelastine (David Ostrov, University of Florida)


33










































Gastroenterology 2020


# Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization


49
















































www.webbertraining.com/schedulep1.php		
April 21, 2021	( <u>South Pacific Teleclass)</u> <u>RETURNING TO WORK DURING COVID-19</u> Speaker: Crystal Polson, University of Melbourne, Australia	
April 27, 2021	(FREE European Teleclass Denver Russell Memorial Teleclass Lecture) HYGIENE BEHAVIOUR IN OUR HOMES AND EVERYDAY LIVES TO MEET 21ST CENTURY NEEDS Speaker: Prof. Sally Bloomfield, International Scientific Forum on Home Hygiene, UK	
May 5, 2021	(FREE WHO Teleclass for May 5 Events) SECONDS SAVE LIVES: CLEAN YOUR HANDS Speaker: Prof. Didier Pittet, University of Geneva Hospitals, Switzerland	
May 11, 2021	(European Teleclass) THE NORWAY EXPERIENCE CONTROLLING THE CORONAVIRUS PANDEMIC Speaker: Prof. Bjørg Marit Andersen, Faculty of Health and Social Science, Department of Nursing and Health Science, University of South-Eastern Norway	

